Products
Latest News
FAQ
Log in
|
Search
Search
Filters
Clear All
Study Phase
Early Phase 1
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
Phase 4
Not Applicable
Recruitment Status
Recruiting
Not yet recruiting
Active, not recruiting
Completed
Suspended
Terminated
Withdrawn
Study Type
Interventional
Observational
Expanded Access
Others
Eligibility Sex
All
Female
Male
Healthy Volunteers
All
Include
Exclude
Found
1
clinical trials
|
View Analysis
Sort by:
Newest First
Autologous Dendritic Cell Vaccine in Kidney Cancer
Phase 2
Recruiting
Conditions
Carcinoma, Renal Cell
Interventions
Biological: Autologous alpha-DC1/TBVA vaccine
Drug: Cabozantinib
Subscribe
First Posted Date
2021-11-19
Last Posted Date
2024-12-12
Lead Sponsor
Jodi Maranchie
Target Recruit Count
42
Registration Number
NCT05127824
Locations
🇺🇸
UPMC Department of Urology, Pittsburgh, Pennsylvania, United States
Subscribe
Prev
1
Next
© Copyright 2025. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy